| Literature DB >> 32539823 |
A Gimeno-García1,2, A Franco-Moreno3, C Montero-Hernández3,4, S Arponen3, E García-Carrasco5, B Alejos6, D Corps-Fernández3,4, E Gaspar-García7, P Galindo-Jara4,8, M García-Navarro3, D Varillas-Delgado4.
Abstract
BACKGROUND: Since the identification of human immunodeficiency virus (HIV) infection, there have been significant advances in its diagnosis and treatment, but there have been few contributions to the area of care quality. In 2010, the Spanish AIDS Study Group (GeSIDA) published the document "Health quality indicators of GeSIDA for the care of people infected with HIV/AIDS" in which standards are proposed for the purpose of improving and standardizing the assistance provided to people infected with HIV. The purpose of this study was to evaluate the degree of compliance with these indicators and to analyse whether adherence to the standards improves patient perception of care quality in terms of their satisfaction with the health care they have received.Entities:
Keywords: Acquired immunodeficiency syndrome; HIV; Health care: patient satisfaction; Quality indicators
Mesh:
Year: 2020 PMID: 32539823 PMCID: PMC7294604 DOI: 10.1186/s12955-020-01441-w
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Characteristics of patients treated in the HIV program stratified by survey participation
| Lost to follow-up, transferred, dead | Did not respond to survey | Responded to survey | Total | ||
|---|---|---|---|---|---|
| Number | 93 | 77 | 164 | 334 | |
| Sex | 0.664 | ||||
| Male | 61 (65.6%) | 46 (59.7%) | 107 (65.2%) | 214 (64.1%) | |
| Female | 32 (34.4%) | 31 (40.3%) | 57 (34.8%) | 120 (35.9%) | |
| Transmission | 0.005 | ||||
| PDA | 35 (37.6%) | 18 (23.4%) | 42 (25.t6%) | 95 (28.4%) | |
| Unknown | 1 (1.1%) | 5 (6.5%) | 2 (1.2%) | 8 (2.4%) | |
| MSM | 15 (16.1%) | 14 (18.2%) | 56 (34.1%) | 85 (25.4%) | |
| Heterosexual | 42 (45.2%) | 40 (51.9%) | 62 (37.8%) | 144 (43.2%) | |
| Blood transfusion | 0 (0.0%) | 0 (0.0%) | 1 (0.6%) | 1 (0.3%) | |
| Vertical | 0 (0.0%) | 0 (0.0%) | 1 (0.6%) | 1 (0.3%) | |
| Country of origin | 0.024 | ||||
| Spain | 56 (60.2%) | 36 (46.8%) | 107 (65.2%) | 199 (59.6%) | |
| Other | 37 (39.8%) | 41 (53.2%) | 57 (34.8%) | 135 (40.4%) | |
| Age at first visit, years | 44.2 (37.2;49.3) | 41.6 (31.9;48.8) | 42.1 (34.1;47.4) | 42.3 (34.6;48.5) | 0.645 |
| Viral load at first visit | |||||
| Undetectable (< 50 copies/ml) | 34 (36.6%) | 39 (50.6%) | 62 (37.8%) | 135 (40.4%) | 0.143 |
| CD4+ cell count at first visit (cells/mm3) | 413.0 (179.0;639.0) | 491.0 (237.0;747.0) | 474.0 (215.5;698.0) | 457.0 (219.0;685.0) | 0.227 |
| Years of follow-up | 1.0 (0.2;1.8) | 4.3 (2.9;5.1) | 3.6 (2.0;4.8) | 2.9 (1.0;4.6) | < 0.001 |
PDA Parenteral drug addiction
MSM Men who have sex with men
Fig. 1General outline of the study: patients included between 2011 and 2017
Quality indicators for all patients evaluated
| N | Indicator | Patients evaluated by the indicator | Patients who met the indicator | Standard set by GeSIDA | Compliance with the indicator in the study | |||
|---|---|---|---|---|---|---|---|---|
| ( | ( | (%) | (CI 95%) | (%) | ||||
| 1 | Specialized doctor care | 100 | 100% | Yes | ||||
| 2 | Availability of diagnostic resources | 100 | Yes (all) | Yes | ||||
| 3 | External pharmacy for dispensing drugs | No | Yes | No | ||||
| 4 | Conditions of privacy and structural confidentiality | 100 | 100% | Yes | ||||
| 6 | Delay in referral to specialized care | 47 | 42 | 89.4 | 76.9 | 96.5 | 100% | No |
| 7 | Late diagnosis of HIV in specialized care | 106 | 28 | 26.4 | 18.3 | 35.9 | < 25% | Yes |
| 8 | HIV diagnosis with previous negative serology | 106 | 64 | 60.4 | 50.4 | 69.7 | 80% | No |
| 10 | Complementary tests in the initial assessment | 334 | 322 | 96.4 | 93.8 | 98.1 | 95% | Yes |
| 11 | HIV plasma viral load | 334 | 334 | 100 | 98.9 | 100 | 100% | Yes |
| 12 | Determination of lymphocyte subpopulations (CD4) | 334 | 334 | 100 | 98.9 | 100 | 100% | Yes |
| 13 | Health education at initial assessment | 332 | 187 | 56.3 | 50.8 | 61.7 | 95% | No |
| 15 | Indication of treatment with < 350 CD4 and without prior ART | 117 | 3 | 2.6 | 0.5 | 7.3 | < 10% | Yes |
| 16 | Periodicity of visits (regular follow-up) | 218 | 193 | 88.5 | 83.5 | 92.4 | 85% | Yes |
| 17 | Basic renal study in HIV+ patients | 212 | 209 | 98.6 | 95.9 | 99.7 | 100% | Yes |
| 20 | LTI detection | 189 | 110 | 58.2 | 50.8 | 65.3 | 90% | No |
| 21 | Vaccination against hepatitis A | 58 | 54 | 93.1 | 83.3 | 98.1 | 85% | Yes |
| 22 | Vaccination against hepatitis B | 88 | 81 | 92.0 | 84.3 | 96.7 | 85% | Yes |
| 23 | Vaccination against pneumococcal infection | 213 | 193 | 90.6 | 85.9 | 94.2 | 85% | Yes |
| 24 | Prophylaxis against | 42 | 41 | 97.6 | 87.4 | 99.9 | 100% | Yes |
| 25 | Treatment and prevention of smoking | 93 | 67 | 72.0 | 61.8 | 80.9 | 95% | No |
| 26 | Alcohol intake assessment | 218 | 8 | 3.7 | 1.6 | 7.1 | 95% | No |
| 29 | Syphilis screening | 149 | 68 | 45.6 | 37.5 | 54.0 | 70% | No |
| 30 | LTI treatment | 25 | 23 | 92.0 | 74.0 | 99.0 | 95% | Yes |
| 31 | Loss to follow-up | 255 | 14 | 5.5 | 3.0 | 9.0 | ≤ 5% | Yes |
| 32 | Recovery of failed appointments | 84.9 | 85% | Yes | ||||
| 35 | Adaptation of initial ART to the guidelines | 119 | 119 | 100 | 96.9 | 100 | 95% | Yes |
| 36 | Initiation of ART in patients with symptomatic B/C events | 33 | 32 | 97.0 | 84.2 | 99.9 | 90% | Yes |
| 37 | First visit after the establishment of ART | 117 | 108 | 92.3 | 85.9 | 96.4 | 90% | Yes |
| 38 | Undetectable viral load (< 50 copies/ml) at week 48 | 106 | 102 | 96.2 | 90.6 | 99.0 | 80% | Yes |
| 39 | Treatment with Abacavir (ABC) without previous HLA-B 5701 | 77 | 0 | 0 | 0 | 4.7 | 0% | Yes |
| 40 | Treatment changes during the first year | 98 | 20 | 20.4 | 12.9 | 29.7 | < 30% | Yes |
| 41 | Record of adherence to treatment | 312 | 266 | 85.3 | 80.8 | 89.0 | 95% | No |
| 42 | Study of resistance in case of virologic failure | 45 | 41 | 91.1 | 78.8 | 97.5 | 90% | Yes |
| 44 | Average expenditure per patient in first treatment | 13 | 8710.8* | ** | Yes | |||
| 45 | ART in pregnant women with HIV | 17 | 17 | 100 | 80.5 | 100 | 100% | Yes |
| 47 | Vertical transmission incidence | 17 | 0 | 0 | 0 | 19.5 | < 1% | Yes |
| 49 | Evaluation by CHILD or MELD for chronic liver disease | 12 | 6 | 50.0 | 21.1 | 78.9 | 100% | No |
| 50 | Evaluation of hepatitis C virus coinfection | 7 | 7 | 100 | 59.0 | 100 | 90% | Yes |
| 54 | HBsAg patients receiving effective treatment | 12 | 12 | 100 | 73.5 | 100 | 90% | Yes |
| 55 | Ultrasound control in cirrhotic patients | 8 | 4 | 50.0 | 15.7 | 84.3 | 90% | No |
| 56 | Cardiovascular risk assessment | 212 | 120 | 56.6 | 49.6 | 63.4 | 90% | No |
| 58 | Patients with discharge report after hospitalization | 80 | 80 | 100 | 95.5 | 100 | 100% | Yes |
| 59 | Reports of discharge of deceased patients in the hospital | 12 | 12 | 100 | 73.5 | 100 | 100% | Yes |
| 60 | Follow-up in outpatient clinic after hospital discharge | 74 | 74 | 100 | 95.1 | 100 | 100% | Yes |
| 62 | Overall mortality rate in patients in follow-up | 334 | 15 | 11.7 | 8.7 | 24.9 | ≤ 25*** | Yes |
| 63 | Mortality rate due to AIDS-related causes | 334 | 3 | 3.2 | 1.0 | 9.8 | Not established | |
| 64 | Continuing education | 100 | 75% | Yes | ||||
* Cost in euros of initiating treatment in this population
** Median rates published in the corresponding year by GeSIDA (7506.5 (6556–9072)) [16]
*** Death rate per 1000 people/year
Fig. 2Results of the satisfaction questionnaire (SUCE) in the interviewed patients
Univariate analysis of quality indicators related to satisfaction (SUCE)
| N | Healthcare quality indicator | SUCE |
|---|---|---|
| Mean difference (CI 95%) | ||
| 6 | Delay in referral to specialized care | −0.26 (−1.33;0.81) |
| 7 | Late diagnosis of HIV in specialized care | −0.23 (− 0.81;0.35) |
| 8 | HIV diagnosis with previous negative serology | −0.10 (− 0.65;0.44) |
| 10 | Complementary tests in the initial assessment | 0.01 (−1.07;1.10) |
| 11 | HIV plasma viral load | – |
| 12 | Determination of lymphocyte subpopulations (CD4) | – |
| 13 | Health education at initial assessment | 0.24 (−0.06;0.54) |
| 15 | Indication of treatment with < 350 CD4 and without prior ART | – |
| 16 | Periodicity of visits (regular follow-up) | 0.62 (0.13;1.11)* |
| 17 | Basic renal study in HIV+ patients | −0.57 (− 2.49;1.35) |
| 20 | LTI detection | 0.09 (−0.27;0.44) |
| 21 | Vaccination against hepatitis A | 1.14 (0.16;2.12)* |
| 22 | Vaccination against hepatitis B | 0.49 (−0.41;1.40) |
| 23 | Vaccination against pneumococcal infection | 0.74 (0.10;1.38)* |
| 24 | Prophylaxis against | −0.14 (−3.03;2.76) |
| 25 | Treatment and prevention of smoking | 0.11 (−0.52;0.75) |
| 26 | Alcohol intake assessment | −1.20 (− 1.97; −0.44)* |
| 29 | Syphilis screening | 0.03 (−0.35;0.41) |
| 30 | LTI treatment | −0.60 (−2.18;0.98) |
| 35 | Adaptation of initial ART guidelines to the guidelines | – |
| 36 | Initiation of ART in patients with symptomatic B/C events | – |
| 37 | First visit after the establishment of ART | −0.69 (−1.61;0.23) |
| 38 | Undetectable viral load (< 50 copies/ml) at week 48 | −0.62 (−2.76;1.52) |
| 39 | Treatment with Abacavir (ABC) without previous HLA-B 5701 | – |
| 40 | Treatment changes during the first year | −0.08 (− 0.87;0.71) |
| 41 | Record of adherence to treatment | 0.33 (− 0.14;0.79) |
| 42 | Study of resistance in case of virologic failure | −0.48 (−1.85;0.90) |
| 45 | ART in pregnant women with HIV | – |
| 47 | Vertical transmission incidence | – |
| 49 | Evaluation by CHILD or MELD for chronic liver disease | 1.67 (−1.34;4.67) |
| 50 | Evaluation of the hepatitis C virus coinfection | – |
| 54 | HBsAg patients receiving effective treatment | – |
| 55 | Ultrasound control in cirrhotic patients | 1.25 (−3.23;5.73) |
| 56 | Cardiovascular risk assessment | −0.01 (− 0.34;0.31) |
* p-value < 0.05
Univariate analysis of other factors related to satisfaction (SUCE)
| Other factors | SUCE |
|---|---|
| Mean difference (CI 95%) | |
| Age | −0.01 (− 0.02;0.01) |
| Level of education | |
| None | 0 |
| Primary | 0.26 (−0.24;0.75) |
| Secondary | 0.02 (−0.47;0.50) |
| University | 0.37 (−0.18;0.93) |
| Sex | |
| Male | 0 |
| Female | 0.18 (−0.12;0.49) |
| HIV transmission category | |
| PDA | 0 |
| MSM | −0.31 (−1.02;0.39) |
| Heterosexual | −0.29 (− 0.97;0.40) |
| Country of origin | |
| Spain | 0 |
| Other | 0.42 (0.12;0.71)* |
| Years since HIV diagnosis | −0.01 (−0.02;0.01) |
| CD4+ count (cells/mm3) at the time of submitting the survey | |
| < 200 | 0 |
| 200–500 | 0.23 (−0.36;0.82) |
| > 500 | 0.35 (−0.19;0.90) |
| Viral load (copies/ml) at the time of delivery of the survey | |
| < 50 | 0 |
| 50–100,000 | 0.07 (−0.36;0.51) |
| > 100,000 | 0.97 (−0.90;2.84) |
* p-value < 0.05
Multivariable analysis of satisfaction-related factors (SUCE)
| Mean difference (CI 95%) | |
|---|---|
| SUCE | |
| Indicator 16 | 0.55 (0.08;1.02) |
| Country of origin (ref. Spain) | |
| Other | 0.36 (0.06;0.66) |